BERKELEY, CA--(Marketwire - Aug 11, 2011) - Dynavax Technologies Corporation (
Brant Biehn, Chief Commercial Officer of Dynavax, and Shari Annes, Investor Relations of Dynavax, will provide a corporate overview presentation. To access the live webcast and the subsequent archived recording of the presentation, please log onto Dynavax's website at http://investors.dynavax.com/newsevents.cfm.
About Dynavax
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. The Company's lead product candidate is HEPLISAV™, a Phase 3 investigational adult hepatitis B vaccine designed to provide rapid and superior protection with fewer doses than current licensed vaccines. For more information visit www.dynavax.com.
Contact Information:
Contact:
Shari Annes
Investor Relations
510-665-7211